The antifungal activity of metal compounds has been investigated even less than their antibacterial properties. Over the last years a small number of reports have been published on several different antifungal metal complexes. Figure presents an overview of selected metal compounds with measured antifungal activity. Gasser and coworkers recently published an expansive review of the metalbased antifungals research field. One issue that the authors noted, in addition to the small number of systematic studies into antifungal metal complexes, is the lack of mode of action studies, and often less than ideal antifungal data collection and reporting with regards to methodology and controls. Only a couple of studies so far have reported the in vivo evaluation of metal-based compounds. Gandra et al. studied a series of phenanthroline complexes containing copper, manganese and silver. They demonstrated that these compounds showed no toxicity in a Galleria mellonella (moth larvae) in vivo model at 10 µg/larva. Additionally, most complexes also reduced the fungal burden of larvae infected with Candida haemulonii. Work by Granato et al. showed that silver complexes with 1,10-phenanthroline-5,6dione were able to protect G. mellonella larvae from infection with Phialophora verrucose. We recently published an antifungal study of a series of cobalt complexes that were initially discovered through the CO-ADD screening program. These compounds (e.g. 5, Figure ) showed excellent in vitro activity against several fungal strains, including ones resistant to several classes of antifungal drugs. We further showed that these compounds displayed no toxicity in a G. mellonella in vivo model at doses up to 266 mg/kg. In 2021, Rubbiani and Gasser et al. described a class of ferrocene-bearing fluconazole derivatives possessing excellent in vitro antifungal activity. The best compound (2, Figure ) was studied in-depth and evaluated in an in vivo mouse model bearing a Candida infection. This organometallic compound was found to diminish the growth of the fungus and improve the inflammatory pathology of the mouse's kidney and colon. Also in 2021, Pavic and Zobi et al. reported a series of rhenium complexes with activity against both Gram-positive bacteria as well as fungi. All compounds were tested for toxicity via a series of in vitro and in vivo assays, with some showing no signs of cardio-, hepato-, hematotoxicity or teratogenicity. Furthermore, the most promising complexes (e.g. 13, Figure ) were shown to inhibit fungal filamentation in an in vivo C. albicans infection study in zebrafish. While these studies are encouraging, there is still a lack of data and systematic studies into metal-based antifungals. The CO-ADD screening panel consists of a selection of ESKAPE bacteria, namely Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Escherichia coli, as well as the pathogenic yeasts Candida albicans and Cryptococcus neoformans. Hence, we have access to an unprecedented array of systematically collected data on the antifungal properties of >300,000 compounds including >1000 metal compounds.